Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 284

1.

Stage I-II Nodular Lymphocyte-Predominant Hodgkin Lymphoma: a Multi-institutional Experience of Adult Patients by ILROG.

Binkley MS, Rauf MS, Milgrom SA, Pinnix CC, Tsang RW, Dickinson M, Ng A, Roberts KB, Gao S, Balogh AG, Ricardi U, Levis M, Casulo C, Stolten M, Specht L, Plastaras JP, Wright C, Kelsey CR, Brady JL, Mikhaeel NG, Hoppe BS, Terezakis S, Picardi M, Della Pepa R, Kirova Y, Akhtar S, Maghfoor I, Koenig JL, Jackson C, Song E, Sehgal S, Advani R, Natkunam Y, Constine LS, Eich HT, Wirth A, Hoppe RT.

Blood. 2020 Mar 25. pii: blood.2019003877. doi: 10.1182/blood.2019003877. [Epub ahead of print]

PMID:
32211877
2.

Radiation therapy for oligometastatic oropharyngeal cancer.

Martini S, Arcadipane F, Franco P, Iorio GC, Bartoncini S, Gallio E, Guarneri AS, Ricardi U.

BJR Case Rep. 2020 Feb 12;6(1):20190021. doi: 10.1259/bjrcr.20190021. eCollection 2020 Mar.

3.

Fondazione Italiana Linfomi (FIL) expert consensus on the use of intensity-modulated and image-guided radiotherapy for Hodgkin's lymphoma involving the mediastinum.

Filippi AR, Meregalli S, DI Russo A, Levis M, Ciammella P, Buglione M, Guerini AE, De Marco G, De Sanctis V, Vagge S, Ricardi U, Simontacchi G; Fondazione Italiana Linfomi (FIL) Radiotherapy Committee.

Radiat Oncol. 2020 Mar 12;15(1):62. doi: 10.1186/s13014-020-01504-8. Review.

4.

Toxicity and cosmetic outcome after hypofractionated whole breast irradiation and boost-IOERT in early stage breast cancer (HIOB): First results of a prospective multicenter trial (NCT01343459).

Fastner G, Reitsamer R, Urbański B, Kopp P, Murawa D, Adamczyk B, Karzcewska A, Milecki P, Hager E, Reiland J, Ciabattoni A, Matuschek C, Budach W, Nowell K, Schumacher C, Ricke A, Fusco V, Vidali C, Alessandro M, Ivaldi GB, Ziegler I, Fussl C, Zehentmayr F, Grambozov B, Sir A, Hitzl W, Ricardi U, Sedlmayer F.

Radiother Oncol. 2020 Mar 6;146:136-142. doi: 10.1016/j.radonc.2020.02.001. [Epub ahead of print]

PMID:
32151790
5.

Mixed-beam approach in locally advanced nasopharyngeal carcinoma: IMRT followed by proton therapy boost versus IMRT-only. Evaluation of toxicity and efficacy.

Alterio D, D'Ippolito E, Vischioni B, Fossati P, Gandini S, Bonora M, Ronchi S, Vitolo V, Mastella E, Magro G, Franco P, Ricardi U, Krengli M, Ivaldi G, Ferrari A, Fanetti G, Comi S, Tagliabue M, Verri E, Ricotti R, Ciardo D, Jereczek-Fossa BA, Valvo F, Orecchia R.

Acta Oncol. 2020 May;59(5):541-548. doi: 10.1080/0284186X.2020.1730001. Epub 2020 Feb 23.

PMID:
32090645
6.

Recommendation for supportive care in patients receiving concurrent chemotherapy and radiotherapy for lung cancer.

De Ruysscher D, Faivre-Finn C, Nackaerts K, Jordan K, Arends J, Douillard JY, Ricardi U, Peters S.

Ann Oncol. 2020 Jan;31(1):41-49. doi: 10.1016/j.annonc.2019.10.003. Review.

PMID:
31912794
7.

Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Zucca E, Arcaini L, Buske C, Johnson PW, Ponzoni M, Raderer M, Ricardi U, Salar A, Stamatopoulos K, Thieblemont C, Wotherspoon A, Ladetto M; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org.

Ann Oncol. 2020 Jan;31(1):17-29. doi: 10.1016/j.annonc.2019.10.010. Epub 2019 Dec 4. No abstract available.

PMID:
31912792
8.

Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation.

Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, Dingemans AC, Fournier B, Hurkmans C, Lecouvet FE, Meattini I, Romero AM, Ricardi U, Russell NS, Schanne DH, Scorsetti M, Tombal B, Verellen D, Verfaillie C, Ost P.

Lancet Oncol. 2020 Jan;21(1):e18-e28. doi: 10.1016/S1470-2045(19)30718-1. Review.

PMID:
31908301
9.

Management of locally advanced non-small cell lung cancer in the modern era: A national Italian survey on diagnosis, treatment and multidisciplinary approach.

Bruni A, Giaj-Levra N, Ciammella P, Maragna V, Ferrari K, Bonti V, Grossi F, Greco S, Greco C, Borghetti P, Franceschini D, Capelletto E, Perna M, Banna G, Vagge S, Baldini E, Bria E, Botti A, Tiseo M, Paci M, Taraborrelli M, Poletti V, Granone P, Ricardi U, Novello S, Scotti V.

PLoS One. 2019 Nov 13;14(11):e0224027. doi: 10.1371/journal.pone.0224027. eCollection 2019.

10.

Treatment paths for localised prostate cancer in Italy: The results of a multidisciplinary, observational, prospective study (Pros-IT CNR).

Buglione M, Noale M, Bruni A, Antonelli A, Bertoni F, Corvo' R, Ricardi U, Borghetti P, Maddalo M, Simeone C, Mazzeo E, Porreca A, Serni S, Bassi P, Gacci M, Mirone V, Montironi R, Tubaro A, Berruti A, Conti GN, Maggi S, Magrini SM, Triggiani L; Pros-IT CNR study group.

PLoS One. 2019 Nov 1;14(11):e0224151. doi: 10.1371/journal.pone.0224151. eCollection 2019.

11.

Proton Therapy For Lymphomas: Current State Of The Art.

Ricardi U, Maraldo MV, Levis M, Parikh RR.

Onco Targets Ther. 2019 Oct 1;12:8033-8046. doi: 10.2147/OTT.S220730. eCollection 2019.

12.

Do hypofraction and large breast size reciprocally fit in breast cancer radiotherapy?

Franco P, Bartoncini S, Martini S, Iorio GC, Ricardi U.

Ann Transl Med. 2019 Jul;7(Suppl 3):S146. doi: 10.21037/atm.2019.06.26. No abstract available.

13.

Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM).

Facchinetti F, Pilotto S, Metro G, Baldini E, Bertolaccini L, Cappuzzo F, Delmonte A, Gasparini S, Inno A, Marchetti A, Passiglia F, Puma F, Ricardi U, Rossi A, Crinò L, Novello S.

Tumori. 2019 Jul;105(5_suppl):3-14. doi: 10.1177/0300891619857418.

PMID:
31264531
14.

The role of radiotherapy in epithelial ovarian cancer: a literature overview.

Iorio GC, Martini S, Arcadipane F, Ricardi U, Franco P.

Med Oncol. 2019 Jun 4;36(7):64. doi: 10.1007/s12032-019-1287-8. Review.

PMID:
31165334
15.

Primary tumor size as a prognosticator in anal cancer patients.

Franco P, Ricardi U.

Ann Transl Med. 2019 Apr;7(7):157. doi: 10.21037/atm.2019.03.16. No abstract available.

16.

Inclusion of heart substructures in the optimization process of volumetric modulated arc therapy techniques may reduce the risk of heart disease in Hodgkin's lymphoma patients.

Levis M, Filippi AR, Fiandra C, De Luca V, Bartoncini S, Vella D, Ragona R, Ricardi U.

Radiother Oncol. 2019 Sep;138:52-58. doi: 10.1016/j.radonc.2019.05.009. Epub 2019 May 27.

PMID:
31146071
17.

Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier).

Casadei-Gardini A, Montagnani F, Casadei C, Arcadipane F, Andrikou K, Aloi D, Prete AA, Zampino MG, Argentiero A, Pugliese G, Martini S, Iorio GC, Scartozzi M, Mistrangelo M, Fornaro L, Cassoni P, Marisi G, Dell'Acqua V, Ravenda PS, Lonardi S, Silvestris N, De Bari B, Ricardi U, Cascinu S, Franco P.

Cancer Manag Res. 2019 Apr 26;11:3631-3642. doi: 10.2147/CMAR.S197349. eCollection 2019. Erratum in: Cancer Manag Res. 2019 Jun 25;11:5123.

18.

Applying radiation protection and safety in radiotherapy.

Magrini SM, Pasinetti N, Belgioia L, Triggiani L, Levis M, Ricardi U, Corvò R.

Radiol Med. 2019 Aug;124(8):777-782. doi: 10.1007/s11547-019-01043-7. Epub 2019 May 18.

PMID:
31104276
19.

Salvage Radical Prostatectomy for Recurrent Prostate Cancer: Morbidity and Functional Outcomes from a Large Multicenter Series of Open versus Robotic Approaches.

Gontero P, Marra G, Alessio P, Filippini C, Oderda M, Munoz F, Linares E, Sanchez-Salas R, Challacombe B, Dasgupta P, Goonewardene S, Popert R, Cahill D, Gillatt D, Persad R, Palou J, Joniau S, Piechaud T, Morlacco A, Vidit S, Rouprêt M, De La Taille A, Albisinni S, Gandaglia G, Mottrie A, Joshi S, Fiscus G, Berger A, Aron M, Van Der Poel H, Tilki D, Lawrentschuk N, Murphy DG, Leung G, Davis J, Karnes RJ; Collaborators.

J Urol. 2019 Oct;202(4):725-731. doi: 10.1097/JU.0000000000000327. Epub 2019 Sep 6.

PMID:
31075058
20.

Hypofractionated radiation therapy versus chemotherapy with temozolomide in patients affected by RPA class V and VI glioblastoma: a randomized phase II trial.

Pedretti S, Masini L, Turco E, Triggiani L, Krengli M, Meduri B, Pirtoli L, Borghetti P, Pegurri L, Riva N, Gatta R, Fusco V, Scoccianti S, Bruni A, Ricardi U, Santoni R, Magrini SM, Buglione M.

J Neurooncol. 2019 Jul;143(3):447-455. doi: 10.1007/s11060-019-03175-2. Epub 2019 May 4.

PMID:
31054101

Supplemental Content

Loading ...
Support Center